Pα+ Psychedelic Bulletin #201 compiles Prague and London dispatches, Texas ibogaine research funding, and fragile high-dose LSD depression signals

High-dose LSD, ibogaine, and psilocybin sit at the center of Psychedelic Alpha Pα+ Bulletin #201, alongside policy and market developments that the newsletter connects across Europe and the US. The bulletin reports dispatches from Prague and London, including a conference at Prague Castle focused on Czechia’s future in EU-aligned mental health policy and the role psychedelics could play in supporting resilience amid war trauma. On the US side, Texas is framed as becoming a leader in ibogaine research, tied to a governor-signed $50M match-funding bill, while a section on a high-dose LSD depression trial highlights potential benefits but also emphasizes fragility of the findings. Overall, the newsletter links conference activity, legislative direction, investor interest, and emerging trial outcomes to track how psychedelic therapy momentum is being built and contested.